Steven Cohen’s Lifecore Biomedical LFCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-52,520
Closed -$276K – 4292
2026
Q2
$276K Buy
52,520
+27,093
+107% +$136K ﹤0.01% 3406
2026
Q1
$94.6K Buy
25,427
+9,771
+62% +$67.5K ﹤0.01% 3617
2025
Q4
$128K Buy
+15,656
New +$116K ﹤0.01% 3709
2023
Q1
– Sell
-141,446
Closed -$917K – 2409
2022
Q4
$917K Sell
141,446
-44,758
-24% -$369K ﹤0.01% 1063
2022
Q3
$1.66M Sell
186,204
-17,496
-9% -$178K 0.01% 965
2022
Q2
$2.03M Sell
203,700
-57,856
-22% -$573K 0.01% 933
2022
Q1
$3.03M Buy
261,556
+84,537
+48% +$941K 0.01% 805
2021
Q4
$1.96M Buy
+177,019
New +$1.72M 0.01% 825

Other funds holding LFCR

Steven Cohen's LFCR Position: Q3 2026 in Review

Steven Cohen sold out of Lifecore Biomedical (LFCR) in Q3 2026, closing a stake of 52,520 shares — an estimated $276K sold.

Steven Cohen first reported a position in LFCR in Q4 2021 and held it in 8 quarters. The position peaked at $3.03M in Q1 2022. 105 funds tracked by Wall St. Rank hold LFCR as of Q3 2026.

  • Steven Cohen reported no remaining Lifecore Biomedical position as of Q3 2026 after selling out during the quarter.
  • Steven Cohen sold 52,520 Lifecore Biomedical shares in Q3 2026, an estimated $276K.
  • Steven Cohen first reported a position in Lifecore Biomedical in Q4 2021 and held it in 8 quarters.
  • Steven Cohen's Lifecore Biomedical position peaked at $3.03M in Q1 2022.
  • 105 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q3 2026.

Based on Point72 Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.